Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1996-10-04
1999-02-16
Ivy, C. Warren
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514 56, 536 21, 536 551, A01N 4304, C07H 504
Patent
active
058721096
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
This invention relates to an anti-inflammatory agent or the like having a new action mechanism. More specifically, this invention relates to a use for treatment or prophylaxis of inflammation, etc. of a sulfated acid mucopolysaccharide or sulfated dextran screened based on a new action mechanism.
BACKGROUND OF THE INVENTION
Nowadays, corticoids or various non-steroidal anti-inflammatory agents are clinically widely used for the purpose of preventing complications due to inflammation. However, since although corticoids exhibit a strong anti-inflammatory action, grave side effects such as induction of infectious diseases accompany the action, they cannot serially be administered, and non-steroidal anti-inflammatory agents have only weak efficacy in general. Therefore, it is still needed to develop anti-inflammatory agents exhibiting almost no side effect and yet having sufficient efficacy.
Incidentally, in the screening systems by which anti-inflammatory agents as mentioned above had been developed, anti-prostaglandin actions (e.g., phospholipase A2 inhibition, cyclooxygenase inhibition, lipoxygenase inhibition) had generally been used as a measure. On the other hand, in this invention, the present inventors intend to solve the above problems from the viewpoint that an utterly novel-type of anti-inflammatory agents may probably be developed by utilizing a screening system constructed based on the findings on induction of inflammation being clarified recently (i.e., a screening system using as a measure inhibition of influx of neutrophils, more specifically, selectin-mediated inhibition of adhesion of neutrophils to vascular endothelial cells).
In order to clarify the sense of the screening system used in the invention, the findings of its background are outlined below. For example, inflammation is speculated to be induced by molecules promoting adhesive interactions between leukocytes and vascular endothelial cells, and it has also come to be clarified that certain adhesion promoting molecules play an important role for promotion of the adhesive interaction. Further, it is also revealed that adhesion promoting molecules exist in both leukocytes and activated vascular endothelial cells (blood vessel at the inflammation site), and interactions between these adhesion promoting molecules are the first indispensable stage for influx of leukocytes to the inflammatory site. These adhesion promoting molecules are molecules found in both leukocytes and activated vascular endothelial cells, and selectin family and integrin family are the most important as the molecules.
On the other hand, it is also reported to use, for control of the above interactions, monoclonal antibodies (Eur. J. Immunol., 23, 2181-2188, 1993), peptides and further certain oligosaccharides (J. Cell Biol., 99, 1535, 1984; Tednok et al., J. Cell Biol., 104, 713, 1987; Blood, 70, 1842, 1987). Further, although leukocytes adhere to endothelial cells in the lymph node through the above action of selectin, it is clarified that this response is inhibited by certain sulfate radical-containing compounds (J. Cell Biol., 111, 1225, 1990). It is still further reported that inflammatory response can be inhibited in various laboratory animal model by inhibiting the above adhesive interactions (J. Immunol., 150, 2407; J. Immunol., 150, 1074 etc.).
However, it is not clarified whether or not these monoclonal antibodies, peptides, oligosaccharides and sulfate radical-containing compounds can actually be used as anti-inflammatory agents.
The present inventors found that the neutrophil-dependent, oxygen radical-mediated and P-, L- or E- selectin-dependent inflammation model obtained by intravenous administration to rats of cobra venom factor (hereafter, sometimes abbreviated as "CVF"), recently proposed in M. S. Mulligan et al., Nature, 364, 149-151, 1993, is an excellent screening method for anti-inflammatory agents. More specifically, they found that specific polysaccharides such as sulfated hyaluronic acid screened using the above laboratory
REFERENCES:
patent: 4840941 (1989-06-01), Ueno et al.
patent: 5013724 (1991-05-01), Petitou et al.
Medline, 89/346421, Modig, "Increased hyaluronic acid production", (1989).
Chemical abstract, vol. 83, No. 188237, Schupp et al, "Response of the formation of collagen fibrils in vito to antiinflammatory agents"(1975).
Chemical abstract, vol. 111, No. 131848, Willershausen et al, Influence of elevated glucose concentrations on the metabolism of gingival fibroblasts, (1989).
T. Tamatani et al., "Characterization of rat LECAM-1 (L-selectin) by the use of monoclonal antibodies and evidence for the presence of soluble LECAM-1 in rat sera", Eur. J. Immunol., vol. 23, pp. 2181-2188, 1993.
L. Stoolman et al., "Phosphomannosyl receptors may participate in the adhesive interaction between lymphocytes and high endothelial venules", J. Cell Biol., vol. 99, pp. 1535-1540, 1984.
T. Yednock et al., "Phosphomannosyl-derivatized beads detect a receptor involved in lymphocyte homing", J. Cell Biol., vol. 104, pp. 713-723, 1987.
L. Stoolman et al., "Homing receptors on human and rodent lymphocytes--evidence for a conserved carbohydrate-binding specificity", Blood, vol. 70, pp. 1842-1850, 1987.
Y. Imai et al., "Direct demonstration of the lactin activity of gp90.sup.mel, a lymphoctye homing receptor", J. Cell Biol., vol. 111, pp. 1225-1232, 1990.
M. Mulligan et al., "Role of .beta..sub.1, .beta..sub.2 integrins and ICAM-1 in lung injury after deposition of IgG and IgA immune complexes.sup.1 ", J. Immunol., vol. 150, pp. 2407-2417, 1993.
K. Kawasaki et al. "Antibodies against intercellular adhesion molecule-1 and lymphocyte function-associated antigen-1 prevent glomerular injury in rat experimental crescentic glomerulonephritis.sup.1 ", J. Immunol., vol. 150, pp. 1074-1083, 1993.
M. Mulligan et al., "Protective effects of oligosaccharides in P-selectin-dependent lung injury", Letters To Nature, vol. 364, 149-151, 1993.
Akima Kazuo
Miyasaka Masayuki
Suzuki Yasuo
Ward Peter A.
Covington Raymond
Ivy C. Warren
Shiseido Company Ltd.
LandOfFree
Anti-inflammatory agent does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-inflammatory agent, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-inflammatory agent will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2062643